Extract
[...] Presentation Gastrointestinal disorders are associated with neurological disorders, particularly peripheral neuropathies In gastroenterology and pain medicine, neuropathic abdominal pain is a major challenge due to its potential to become disabling and resistant to current therapies. The nerves that innervate the abdominal cavity, when damaged, can be responsible for this pain, particularly in conditions such as irritable bowel syndrome, nerve trunk neuralgia, or postoperative abdominal pain. Although many pharmacological and non-pharmacological therapies are available, the results remain unsatisfactory. Pharmacological alternatives such as nonsteroidal anti-inflammatory drugs, opioids, antidepressants, and anticonvulsants are associated with high rates of adverse effects and decreased analgesic efficacy The success rates of treating neuropathic abdominal pain range from 30 to 50%. [...]
[...] Deviation Std. Error Mean Pair 1 EVA avant 8.48 25 1.475 .295 EVA après 4.00 25 2.754 .551 Paired Samples Correlations N Correlation Sig. Pair 1 EVA before & EVA after 25 .144 .494 Paired Samples Test Paired Differences t df Sig. (2-tailed) Mean Std. Deviation Std. Error Mean 95% Confidence Interval of the Difference Lower Upper Pair 1 EVA avant - EVA after 4.480 2.931 .586 3.270 5.690 7.641 24 .000 Paired Samples Effect Sizes Standardizera Point Estimate 95% Confidence Interval Lower Upper Pair 1 EVA before - EVA after Cohen's d 2.931 1.528 .939 2.103 Hedges' correction 2.978 1.504 .924 2.070 Figure Mean (8.48) of the abdominal neuropathic pain before BOTOX Figure Mean (4.00) of the abdominal neuropathic pain after BOTOX The paired t-test results show a significant reduction in pain measured by EVA after the intervention. [...]
[...] Apr 2008;4(4):283-95. 5. Wei Zhu Yang Shen Xie Zuo et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.-analysis of randomized controlled trials. Brain Behav Sept 2019;9(10): e01409. 6. Dekhne Goklani HD, Doshi Baskara Salian Gandhi SK, Patel P. Effectiveness of Botulinum Toxin in the Treatment of Neuropathic Pain: A Literature Review. Cureus. 15(10): e46848. [...]
[...] However, a key question raised by this reduction is its sustainability; since Botox injections are a temporary intervention, it is essential to assess whether patients can maintain the change long-term or whether they will need to resort to other therapies once the Botox is metabolized. However, the study has several limitations. Firstly, the sample size, which does not allow for generalization of the results. Consequently, with quality of life analyses and employment return rates, the statistical power is low and few other variables are statistically significant. Furthermore, a larger database would allow for more refined statistical analysis and searching for trends that may not be significant here. Secondly, the retrospective nature of the study is another limitation. [...]
[...] All these patients were treated from September to March The inclusion criteria were: neuropathic pain of the abdominal wall post-surgery, > 18 years, treatment with Botox injection via TAP Block under ultrasound guidance. The non-inclusion criteria were the etiology of Botox injection for non-neuropathic purposes or non-response to telephone questionnaires. Patients lost to follow-up, deceased, or already injected with Botox before Goni Moreno's intervention were excluded from the analysis. The questionnaire administered consisted of sections detailing : 1. The sociodemographic and clinical data (age, sex, profession, medical history, characteristics of the pain). 2. The pain scores before and after treatment, evaluated using the Visual Analog Scale (VAS). [...]
